Overview

Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Status:
Not yet recruiting
Trial end date:
2028-01-31
Target enrollment:
Participant gender:
Summary
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Viewpoint Molecular Targeting